Punnee Pittisuttithum, Department of Clinical Tropical Medicine, FTM

Name: Punnee Pitisuttithum

ชื่อ-สกุล: ศ.เกียรติคุณ พญ.พรรณี ปิติสุทธิธรรม

Position: Professor

Department: Clinical Tropical Medicine

punnee.pit@mahidol.ac.th

Video

Last updated:February 9, 2023

Publications

2023

Muangnoicharoen S, Wiangcharoen R, Nanthapisal S, Kamolratakul S, Lawpoolsri S, Jongkaewwattana A, Thitithanyanont A, Luvira V, Chinwangso P, Thanthamnu N, Chantratita N, Lim JK, Anh Wartel T, Excler JL, Ryser MF, Leong C, Mak TK, Pitisuttithum P. Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial. Vaccine. 2023 Jun 15:S0264-410X(23)00718-1.

Halsey N, Evans S, Santosham M, Hacker A, Edwards KM, Chandler RE, Dudley MZ, Dekker CL; members of the SPEAC meta-DSMB; Al-Abri S, Arora N, Buttery J, Dodoo A, Eskola J, Heininger U, Jee Y, Khuri N, Obaro S, Orenstein W, Pitisuttithum P, Safadi M, Whitney CG, Black S. Considerations for unblinding individual study participants during vaccine trials. Vaccine. 2023;41(22):3399-3402.

Niyomnaitham S, Jongkaewwattana A, Meesing A, Pinpathomrat N, Nanthapisal S, Hirankarn N, Siwamogsatham S, Kirdlarp S, Chaiwarith R, Lawpoolsri S, Phanthanawiboon S, Thitithanyanont A, Hansasuta P, Chaiyaroj S, Pitisuttithum P. Immunogenicity of a fractional or full third dose of AZD1222 vaccine or BNT162b2 messenger RNA vaccine after two doses of CoronaVac vaccines against the Delta and Omicron variants. International Journal of Infectious Diseases. 2023;129:19-31.

Carreño JM, Raskin A, Singh G, Tcheou J, Kawabata H, Gleason C, Srivastava K, Vigdorovich V, Dambrauskas N, Gupta SL, González Domínguez I, Martinez JL, Slamanig S, Sather DN, Raghunandan R, Wirachwong P, Muangnoicharoen S, Pitisuttithum P, Wrammert J, Suthar MS, Sun W, Palese P, García-Sastre A, Simon V, Krammer F. An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccination. Sci Transl Med. 2023 Feb 15;15(683):eabo2847. doi: 10.1126/scitranslmed.abo2847. Epub 2023 Feb 15. PMID: 36791207.

Horvath A, Rogers L, Pollakis G, Baranov O, Pieroth N, Joseph S, Chachage M, Heitzer A, Maganga L, Msafiri F, Joachim A, Viegas E, Eller LA, Kibuuka H, Rerks-Ngarm S, Pitisuttithum P, Nitayapan S, Dhitavat J, Premsri N, Fidler S, Shattock RJ, Robb ML, Weber J, McCormack S, Munseri PJ, Lyamuya E, Nilsson C, Kroidl A, Hoelscher M, Wagner R, Geldmacher C, Held K. Systematic comparison of HIV-1 Envelope-specific IgG responses induced by different vaccination regimens: Can we steer IgG recognition towards regions of viral vulnerability? Frontiers in Immunology. 2023;13.

2022

Siribhadra A, Ngamprasertchai T, Rattanaumpawan P, Lawpoolsri S, Luvira V, Pitisuttithum P. Antimicrobial Stewardship in Tropical Infectious Diseases: Focusing on Dengue and Malaria. Tropical Medicine and Infectious Disease. 2022;7(8).

Pitisuttithum P, Luvira V, Lawpoolsri S, Muangnoicharoen S, Kamolratanakul S, Sivakorn C, et al. Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial. eClinicalMedicine. 2022;45.

McIntyre PB, Aggarwal R, Jani I, Jawad J, Kochhar S, MacDonald N, Madhi SA, Mohsni E, Mulholland K, Neuzil KM, Nohynek H, Olayinka F, Pitisuttithum P, Pollard AJ, Cravioto A. COVID-19 vaccine strategies must focus on severe disease and global equity. The Lancet. 2022;399(10322):406-10.

Madsalae K, Ngamprasertchai T, Lawpoolsri S, Sirijatuphat R, Ratanasuwan W, Piyaphanee W, Pitisuttithum P. Adherence and Health Problems in Thai Travellers Living with HIV. Tropical Medicine and Infectious Disease. 2022;7(7).

Lemke MM, Theisen RM, Bozich ER, McLean MR, Lee CY, Lopez E, Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kratochvil S, Wines BD, Hogarth PM, Kent SJ, Chung AW, Arnold KB. A Quantitative Approach to Unravel the Role of Host Genetics in IgG-FcγR Complex Formation After Vaccination. Frontiers in Immunology. 2022;13.

Lee GY, Inthasorn P, Laowahutanont P, Lawpoolsri S, Kamolratanakul S, Lungchukiet P, Oh J, Termrungruanglert W, Taechakraichana N, Pitisuttithum P. Long-term effectiveness of human papillomavirus vaccines among adult women: A real-world scenario. Vaccine. 2022;40(13):1968-76.

Crowell TA, Nitayaphan S, Sirisopana N, Wansom T, Kitsiripornchai S, Francisco L, Li Q, Dear N, O'Connell RJ, Pitisuttithum P, Vasan S; RV348B Study Group. Factors associated with testing for HIV and other sexually transmitted infections in men who have sex with men and transgender women in Bangkok, Thailand. AIDS Research and Therapy. 2022;19(1).

Banniettis N, Wysocki J, Szenborn L, Phongsamart W, Pitisuttithum P, Rämet M, Richmond P, Shi Y, Dagan R, Good L, Papa M, Lupinacci R, McFetridge R, Tamms G, Churchill C, Musey L, Bickham K; V114-024 PNEU-PLAN study group. A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants, children, and adolescents (PNEU-PLAN). Vaccine. 2022;40(44):6315-25.

2021

Kamolratanakul S, Pitisuttithum P. Human Papillomavirus Vaccine Efficacy and Effectiveness against Cancer. Vaccines (Basel). 2021 Nov 30;9(12):1413.

Prapaso S, Luvira V, Lawpoolsri S, Songthap A, Piyaphanee W, Chancharoenthana W, Muangnoicharoen S, Pitisuttithum P, Chanthavanich P. Knowledge, attitude, and practices toward COVID-19 among the international travelers in Thailand. Trop Dis Travel Med Vaccines. 2021 Nov 15;7(1):29.

Moore KA*, Ostrowsky JT, Kraigsley AM, Mehr AJ, Bresee JS, Friede MH, Gellin BG, Golding JP, Hart PJ, Moen A, Charlotte LW, Osterholm MT, Ampofo W, Barclay W, Cavaleri M, Cohen C, Cowling B, Cox R, Gust I, Innis B, Kang G, Katz J, Krammer F, Pitisuttithum P, Post D, Rudenko L, Siqueira M, Weir J. A Research and Development (R&D) roadmap for influenza vaccines: Looking toward the future. Vaccine. 2021 Oct 29;39(45):6573-84.

Lemke MM, McLean MR, Lee CY, Lopez E, Bozich ER, Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kratochvil S, Wines BD, Hogarth PM, Kent SJ, Chung AW, Arnold KB. A systems approach to elucidate personalized mechanistic complexities of antibody-Fc receptor activation post-vaccination. Cell Rep Med. 2021 Sep 21;2(9):100386.

Shangguan S, Ehrenberg PK, Geretz A, Yum L, Kundu G, May K, Fourati S, Nganou-Makamdop K, Williams LD, Sawant S, Lewitus E, Pitisuttithum P, Nitayaphan S, Chariyalertsak S, Rerks-Ngarm S, Rolland M, Douek DC, Gilbert P, Tomaras GD, Michael NL, Vasan S, Thomas R. Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as a potential mechanism of vaccine-induced protection against HIV-1. Elife. 2021 Sep 17;10.

Li Y, Bai H, Sanders-Buell E, Dussupt V, Townsley S, Donofrio G, Bose M, O'Sullivan AM, Kibuuka H, Maganga L, Nitayaphan S, Kosgei J, Pitisuttithum P, Rerks-Ngarm S, Eller LA, Michael NL, Robb ML, Ake J, Vasan S, Tovanabutra S, Krebs SJ, Rolland M. Limited Evidence for a Relationship between HIV-1 Glycan Shield Features in Early Infection and the Development of Neutralization Breadth. J Virol. 2021 Aug 10;95(17):e0079721.

Wansom T, Muangnoicharoen S, Nitayaphan S, Kitsiripornchai S, Crowell TA, Francisco L, Gilbert P, Rwakasyaguri D, Dhitavat J, Li Q, King D, Robb ML, Smith K, Heger EA, Akapirat S, Pitisuttithum P, O'Connell RJ, Vasan S. Risk Factors for HIV sero-conversion in a high incidence cohort of men who have sex with men and transgender women in Bangkok, Thailand. EClinicalMedicine. 2021 July 17;38:101033.

Lewitus E, Sanders-Buell E, Bose M, O'Sullivan AM, Poltavee K, Li Y, Bai H, Mdluli T, Donofrio G, Slike B, Zhao H, Wong K, Chen L, Miller S, Lee J, Ahani B, Lepore S, Muhammad S, Grande R, Tran U, Dussupt V, Mendez-Rivera L, Nitayaphan S, Kaewkungwal J, Pitisuttithum P, Rerks-Ngarm S, O'Connell RJ, Janes H, Gilbert PB, Gramzinski R, Vasan S, Robb ML, Michael NL, Krebs SJ, Herbeck JT, Edlefsen PT, Mullins JI, Kim JH, Tovanabutra S, Rolland M. RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infection. Virus Evol. 2021 Jul 9;7(2):veab057.

Beran J, Reynales H, Poder A, Yu CY, Pitisuttithum P, Yuan LL, Vermeulen W, Verhoeven C, Leav B, Zhang B, Sawlwin D, Hamers-Heijnen E, Edelman J, Smolenov I. Prevention of influenza during mismatched seasons in older adults with an MF59-adjuvanted quadrivalent influenza vaccine: a randomised, controlled, multicentre, phase 3 efficacy study. Lancet Infect Dis. 2021 Jul 9;21(7):1027-37.

Pitisuttithum P, Dhitavat J, Sirivichayakul C, Pitisuthitham A, Sabmee Y, Chinwangso P, Kerdsomboon C, Fortuna L, Spiegel J, Chauhan M, Poredi IK, van den Biggelaar AHJ, Wijagkanalan W, Viviani S, Mansouri S, Pham HT. Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aP(gen) or combined TdaP(gen) vaccines. EClinicalMedicine. 2021 Jun 23;37:100976.

Vasan S, Pitisuttithum P. Vaccine development lessons between HIV and COVID-19. Lancet Infect Dis. 2021 June;21(6):759-61.

Levine MM, Abdullah S, Arabi YM, Darko DM, Durbin AP, Estrada V, Jamrozik E, Kremsner PG, Lagos R, Pitisuttithum P, Plotkin SA, Sauerwein R, Shi SL, Sommerfelt H, Subbarao K, Treanor JJ, Vrati S, King D, Balasingam S, Weller C, Aguilar AO, Cassetti MC, Krause PR, Restrepo AMH. Viewpoint of a WHO Advisory Group Tasked to Consider Establishing a Closely-monitored Challenge Model of Coronavirus Disease 2019 (COVID-19) in Healthy Volunteers. Clin Infect Dis. 2021 Jun 1;72(11):2035-41.

Osman M, Manosuthi W, Kaewkungwal J, Silachamroon U, Mansanguan C, Kamolratanakul S, Pitisuttithum P. Etiology, Clinical Course, and Outcomes of Pneumonia in the Elderly: A Retrospective and Prospective Cohort Study in Thailand. Am J Trop Med Hyg. 2021 May 3;104(6):2009-16.

Bornstein J, Roux S, Kjeld Petersen L, Huang LM, Dobson SR, Pitisuttithum P, Diez-Domingo J, Schilling A, Ariffin H, Tytus R, Rupp R, Senders S, Engel E, Ferris D, Kim YJ, Tae Kim Y, Kurugol Z, Bautista O, Nolan KM, Sankaranarayanan S, Saah A, Luxembourg A. Three-Year Follow-up of 2-Dose Versus 3-Dose HPV Vaccine. Pediatrics. 2021 Jan;147(1):e20194035.

2020

Easterhoff D, Pollara J, Luo K, Janus B, Gohain N, Williams LD, Tay MZ, Monroe A, Peachman K, Choe M, Min S, Lusso P, Zhang P, Go EP, Desaire H, Bonsignori M, Hwang KK, Beck C, Kakalis M, O'Connell RJ, Vasan S, Kim JH, Michael NL, Excler JL, Robb ML, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Nitayaphan S, Sinangil F, Tartaglia J, Phogat S, Wiehe K, Saunders KO, Montefiori DC, Tomaras GD, Moody MA, Arthos J, Rao M, Joyce MG, Ofek G, Ferrari G, Haynes BF. HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functions. JCI Insight. 2020 Jan 30;5(2).

Easterhoff D, Pollara J, Luo K, Tolbert WD, Young B, Mielke D, Jha S, O'Connell RJ, Vasan S, Kim J, Michael NL, Excler JL, Robb ML, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Nitayaphan S, Sinangil F, Tartaglia J, Phogat S, Kepler TB, Alam SM, Wiehe K, Saunders KO, Montefiori DC, Tomaras GD, Moody MA, Pazgier M, Haynes BF, Ferrari G. Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency. J Virol. 2020 Jan 31;94(4).

Fischinger S, Shin S, Boudreau CM, Ackerman M, Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kim JH, Robb ML, Michael NL, O'Connell RJ, Vasan S, Streeck H, Alter G. Protein-based, but not viral vector alone, HIV vaccine boosting drives an IgG1-biased polyfunctional humoral immune response. JCI Insight. 2020 Jun 18;5(12).

Fischinger S, Dolatshahi S, Jennewein MF, Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Michael N, Vasan S, Ackerman ME, Streeck H, Alter G. IgG3 collaborates with IgG1 and IgA to recruit effector function in RV144 vaccinees. JCI Insight. 2020 Nov 5;5(21).

Kongchanagul A, Samnuan K, Wirachwong P, Surichan S, Puthavathana P, Pitisuttithum P, Boonnak K. A live attenuated H5N2 prime- inactivated H5N1 boost vaccination induces influenza virus hemagglutinin stalk specific antibody responses. Vaccine. 2020 Jan 22;38(4):852-58.

MacKay D, Jecker NS, Pitisuttithum P, Saylor KW. Selecting participants fairly for controlled human infection studies. Bioethics. 2020 Oct;34(8):771-84.

Olsson SE, Restrepo JA, Reina JC, Pitisuttithum P, Ulied A, Varman M, Van Damme P, Moreira ED, Jr., Ferris D, Block S, Bautista O, Gallagher N, McCauley J, Luxembourg A. Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up. Papillomavirus Res. 2020 Dec;10:100203.

Pitisuttithum P, Nitayaphan S, Chariyalertsak S, Kaewkungwal J, Dawson P, Dhitavat J, Phonrat B, Akapirat S, Karasavvas N, Wieczorek L, Polonis V, Eller MA, Pegu P, Kim D, Schuetz A, Jongrakthaitae S, Zhou Y, Sinangil F, Phogat S, Diazgranados CA, Tartaglia J, Heger E, Smith K, Michael NL, Excler JL, Robb ML, Kim JH, O'Connell RJ, Vasan S. Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial. Lancet HIV. 2020 Apr;7(4):e238-48.

Pitisuttithum P, Marovich MA. Prophylactic HIV vaccine: vaccine regimens in clinical trials and potential challenges. Expert Rev Vaccines. 2020 Feb;19(2):133-42.

Vesikari T, Ramsey K, Pitisuttithum P, Capeding R, Heijnen E, Sawlwin D, Oberyé J, Zhang B, Smolenov I. Repeated exposure to an MF-59 adjuvanted quadrivalent subunit influenza vaccine (aQIV) in children: Results of two revaccination studies. Vaccine. 2020 Dec 3;38(51):8224-31.

Zhao LP, Fiore-Gartland A, Carpp LN, Cohen KW, Rouphael N, Fleurs L, Dintwe O, Zhao M, Moodie Z, Fong Y, Garrett N, Huang Y, Innes C, Janes HE, Lazarus E, Michael NL, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Robb ML, De Rosa SC, Corey L, Gray GE, Seaton KE, Yates NL, McElrath MJ, Frahm N, Tomaras GD, Gilbert PB. Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans. PLoS One. 2020;15(1):e0226803.

2019

Fourati S, Ribeiro SP, Blasco Tavares Pereira Lopes F, Talla A, Lefebvre F, Cameron M, Kaewkungwal J, Pitisuttithum P, Nitayaphan S, Rerks-Ngarm S, Kim JH, Thomas R, Gilbert PB, Tomaras GD, Koup RA, Michael NL, McElrath MJ, Gottardo R, Sekaly RP. Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccine. Nat Commun. 2019 Feb; 10: 863.

Martin M, Vanichseni S, Sangkum U, Mock PA, Leethochawalit M, Chiamwongpaet S, Pitisuttithum P, Kaewkungwal J, van Griensven F, McNicholl JM, Tappero JW, Mastro TD, Kittimunkong S, Choopanya K. HIV Incidence and Risk Behaviours of People Who Inject Drugs in Bangkok, 1995-2012. EClinicalMedicine. 2019 Apr 1;9:44-51.

Pitisuttithum P, Wirachwong P. A review of epidemic preparedness for influenza through local vaccine production: national security for Thailand. Hum Vaccin Immunother. 2019;15(10):2440-2445.

Zhang L, Irimia A, He L, Landais E, Rantalainen K, Leaman DP, Vollbrecht T, Stano A, Sands DI, Kim AS; IAVI Protocol G Investigators, Poignard P, Burton DR, Murrell B, Ward AB, Zhu J, Wilson IA, Zwick MB. IAVI Protocol G Investigators: Miiro G, Serwanga J, Pozniak A, McPhee D, Manigart O, Mwananyanda L, Karita E, Inwoley A, Jaoko W, DeHovitz J, Bekker L, Pitisuttithum P, Paris R, Allen S. An MPER antibody neutralizes HIV-1 using germline features shared among donors. Nat Commun. 2019 Nov 26;10(1):5389.

2018

Garland SM, Joura EA, Ault KA, Bosch FX, Brown DR, Castellsague X, Ferenczy A, Ferris DG, Giuliano AR, Hernandez-Avila M, Huh WK, Iversen OE, Kjaer SK, Kurman RJ, Luna J, Monsonego J, Munoz N, Paavonen J, Pitisuttihum P, Ronnett BM, Steben M, Stoler MH, Wheeler CM, Wiley DJ, Perez G, Saah AJ, Luxembourg A, Li S, DiNubile MJ, Wagner M, Velicer C. Human Papillomavirus Genotypes From Vaginal and Vulvar Intraepithelial Neoplasia in Females 15-26 Years of Age. Obstet Gynecol. 2018 Aug; 132(2): 261-70.

Pitisuttithum P, Chokephaibulkit K, Sirivichayakul C, Sricharoenchai S, Dhitavat J, Pitisuthitham A, Phongsamart W, Boonnak K, Lapphra K, Sabmee Y, Wittawatmongkol O, Chauhan M, Wijagkanalan W, Hommalai G, Fortuna L, Chinwangso P, Poredi IK, van den Biggelaar AHJ, Pham HT, Viviani Sal. Antibody persistence after vaccination of adolescents with monovalent and combined acellular pertussis vaccines containing genetically inactivated pertussis toxin: a phase 2/3 randomised, controlled, non-inferiority tri. Lancet Infect Dis. 2018 Nov; 18(11): 1260-8.

Pasin C, Halloran ME, Gilbert PB, Langevin E, Ochiai RL, Pitisuttithum P, Capeding MR, Carrasquilla G, Frago C, Cortes M, Chambonneau L, Moodie Z. Periods of high dengue transmission defined by rainfall do not impact efficacy of dengue vaccine in regions of endemic disease. PLoS ONE. 2018 Dec; 13(12): e0207878.

Wills S, Hwang KK, Liu P, Dennison SM, Tay MZ, Shen X, Pollara J, Lucas JT, Parks R, Rerks-Ngarm S, Pitisuttithum P, Nitayapan S, Kaewkungwal J, Thomas R, Kim JH, Michael NL, Robb ML, McRaven M, Montefiori DC, Hope TJ, Liao HX, Moody MA, Ferrari G, Haynes BF, Alam SM, Bonsignori M, Tomaras GD. HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis. Journal of Virology. 2018 Apr; 92(7): e01552-17.

Ndaya-Oloo P, Pitisuttithum P, Tornieporth NG, Desgrandchamps D, Munoz FM, Kochhar S, Buttery J, Bauwens J, Bonhoeffer J. Vaccine Update: Recent Progress With Novel Vaccines, and New Approaches to Safety Monitoring and Vaccine Shortage. J Clin Pharmacol. 2018 Oct;58

Pissani F, Schulte B, Eller MA, Schultz BT, Ratto-Kim S, Marovich M, Thongcharoen P, Sriplienchan S, Rerks-Ngarm S, Pitisuttithum P, Esser S, Alter G, Robb ML, Kim JH, Michael NL, Streeck H10. Modulation of Vaccine-induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans. J Virol. Sep 12. pii: JVI.01143-18.

Barouch DH, Tomaka FL, Wegmann F, Stieh DJ, Alter G, Robb ML, Michael NL, Peter L, Nkolola JP, Borducchi EN, Chandrashekar A, Jetton D, Stephenson KE, Li W, Korber B, Tomaras GD, Montefiori DC, Gray G, Frahm N, McElrath MJ, Baden L, Johnson J, Hutter J, Swann E, Karita E, Kibuuka H, Mpendo J, Garrett N, Mngadi K, Chinyenze K, Priddy F, Lazarus E, Laher F, Nitayapan S, Pitisuttithum P, Bart S, Campbell T, Feldman R, Lucksinger G, Borremans C, Callewaert K, Roten R, Sadoff J, Scheppler L, Weijtens M, Feddes-de Boer K, van Manen D, Vreugdenhil J, Zahn R, Lavreys L, Nijs S, Tolboom J, Hendriks J, Euler Z, Pau MG, Schuitemaker H. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Lancet. 2018 Jul 21;392(10143):232-243.

Scinto HB, Gupta S, Thorat S, Mukhtar MM, Griffiths A, Delgado J, Plake E, Vyas HK, Strickland A, Byrareddy SN, Montefiori DC, LaBranche C, Pal R, Treece J, Orndorff S6, Ferrari MG, Weiss D, Chenine AL, McLinden R, Michael N, Kim JH7, Robb ML, Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Ruprecht RM. Novel Strategy To Adapt Simian-Human Immunodeficiency Virus E1 Carrying env from an RV144 Volunteer to Rhesus Macaques: Coreceptor Switch and Final Recovery of a Pathogenic Virus with Exclusive R5 Tropism. J Virol. 2018 Jun 29;92(14).

Yates NL, deCamp AC, Korber BT, Liao HX, Irene C, Pinter A, Peacock J, Harris LJ, Sawant S, Hraber P, Shen X, Rerks-Ngarm S, Pitisuttithum P, Nitayapan S, Berman PW, Robb ML, Pantaleo G, Zolla-Pazner S, Haynes BF, Alam SM, Montefiori DC, Tomaras GD*.HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees. Journal of Virology. 2018 Apr92(8): e01843-17

Akapirat S, Karnasuta C, Vasan S, Rerks-Ngarm S, Pitisuttithum P, Madnote S, Savadsuk H, Rittiroongrad S, Puangkaew J, Phogat S, Tartaglia J, Sinangil F, de Souza MS, Excler JL, Kim JH, Robb ML, Michael NL, Ngauy V, O'Connell RJ, Karasavvas N*. Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations. PLoS One. 2018 Apr 13(4): e0196397

Plennevaux E*, Moureau A, Arredondo-Garcia JL, Villar L, Pitisuttithum P, Tran NH, Bonaparte M, Chansinghakul D, Coronel DL, L'Azou M, Leon Ochiai R, Toh ML, Noriega F, Bouckenooghe A. Impact of Dengue Vaccination on Serological Diagnosis: Insights From Phase III Dengue Vaccine Efficacy Trials. Clinical Infectious Diseases. 2018 Apr 66(8): 1164–72

Auclair S, Liu F, Niu Q, Hou W, Churchyard G, Morgan C, Frahm N, Nitayaphan S, Pitisuthithum P, Rerks-Ngarm S, Kimata JT, Soong L, Franchini G, Robb M, Kim J, Michael N, Hu H. Distinct susceptibility of HIV vaccine vector-induced CD4 T cells to HIV infection. PLoS Pathogens. 2018 Feb 14(2): e1006888

Garland SM*, Pitisuttithum P, Ngan HYS, Cho CH, Lee CY, Chen CA, Yang YC, Chu TY, Twu NF, Samakoses R, Takeuchi Y, Cheung TH, Kim SC, Huang LM, Kim BG, Kim YT, Kim KH, Song YS, Lalwani S, Kang JH, Sakamoto M, Ryu HS, Bhatla N, Yoshikawa H, Ellison MC, Han SR, Moeller E, Murata S, Ritter M, Sawata M, Shields C, Walia A, Perez G, Luxembourg A. Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries. Journal of Infectious Diseases. 2018 Jun 218(1): 95-108

Sricharoenchai S, Sirivichayakul C, Chokephaibulkit K, Pitisuttithum P, Dhitavat J, Pitisuthitham A, Phongsamart W, Boonnak K, Lapphra K, Sabmee Y, Wittawatmongkol O, Chinwangso P, Poredi IK, Petre J, Thai PH, Viviani S*. A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial. Lancet Infectious Diseases. 2018 Jan 18(1): 58-67

2017

Boonnak K, Dhitavat J, Thantamnu N, Kosoltanapiwat N, Auayporn M, Jiang L, Puthavathana P, Pitisuttithum P. Immune responses to intradermal and intramuscular inactivated influenza vaccine among older age group. Vaccine. 2017 Dec 35(52): 7339-46

El Fezzazi H, Branchu M, Carrasquilla G, Pitisuttithum P, Perroud AP, Frago C, Coudeville L*.Resource Use and Costs of Dengue: Analysis of Data from Phase III Efficacy Studies of a Tetravalent Dengue Vaccine. American Journal of Tropical Medicine and Hygiene. 2017 Dec 97(6): 1898-903.

Wang K, Tomaras GD, Jegaskanda S, Moody MA, Liao HX, Goodman KN, Berman PW, Rerks-Ngarm S, Pitisuttithum P, Nitayapan S, Kaewkungwal J, Haynes BF, Cohen JI*. Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1. Journal of Virology. 2017 Oct 91(19): e00411-17

Perez LG, Martinez DR, deCamp AC, Pinter A, Berman PW, Francis D, Sinangil F, Lee C, Greene K, Gao H, Nitayaphan S, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Tartaglia J, O'Connell RJ, Robb ML, Michael NL, Kim JH, Gilbert P, Montefiori DC*.V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144. PLoS One. 2017 Jul 12(7): e0180720.

Gilbert PB, Excler JL, Tomaras GD, Carpp LN, Haynes BF, Liao HX, Montefiori DC, Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Kijak GH, Tovanabutra S, Francis DP, Lee C, Sinangil F, Berman PW, Premsri N, Kunasol P, O'Connell RJ, Michael NL, Robb ML, Morrow R, Corey L, Kim JH.Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women. PLoS One. 2017 May 11;12(5):e0176428. Harrison SC, Haynes BF, Karnasuta C, et al. Comparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination Regimens. PLoS pathogens 2017; 33(5): 410-23.

Wills S, Hwang KK, Liu P, Dennison SM, Tay MZ, Shen X, Pollara J, Lucas JT, Parks R, Rerks-Ngarm S, Pitisuttithum P, Nitayapan S, Kaewkungwal J, Thomas R, Kim JH, Michael NL, Robb ML, McRaven M, Montefiori DC, Hope TJ, Liao HX, Moody MA, Ferrari G, Haynes BF, Alam SM, Bonsignori M, Tomaras GD. HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis. Journal of Virology. 2018 Apr 92(7): e01552-17

Wang Y, Whittall T, Neil S, Britton G, Mistry M, Rerks-Ngarm S, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Yu X, Sato A, O'Connell RJ, Michael NL, Robb ML, Kim JH, Lehner T. A novel mechanism linking memory stem cells with innate immunity in protection against HIV-1 infection. Sci Rep. 2017 Apr 21;7(1):1057.

Pitisuttithum P*, Boonnak K, Chamnanchanunt S, Puthavathana P, Luvira V, Lerdsamran H, Kaewkungwal J, Lawpoolsri S, Thanachartwet V, Silachamroon U, Masamae W, Schuetz A, Wirachwong P, Thirapakpoomanunt S, Rudenko L, Sparrow E, Friede M, Kieny M-P. Safety and immunogenicity of a live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 H5N2 and its priming effects for potential pre-pandemic use: a randomised, double-blind, placebo-controlled trial. Lancet Infectious Diseases. 2017 Aug 17(8): 833-42

Rerks-Ngarm S, Pitisuttithum P, Excler JL, Nitayaphan S, Kaewkungwal J, Premsri N, Kunasol P, Karasavvas N, Schuetz A, Ngauy V, Sinangil F, Dawson P, deCamp AC, Phogat S, Garunathan S, Tartaglia J, DiazGranados C, Ratto-Kim S, Pegu P, Eller M, Karnasuta C, Montefiori DC, Sawant S, Vandergrift N, Wills S, Tomaras GD, Robb ML, Michael NL, Kim JH, Vasan S, O'Connell RJ; RV305 Study Team. Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial. J Infect Dis. 2017 Apr 15;215(8):1255-1263.

Easterhoff D, Moody MA, Fera D, Cheng H, Ackerman M, Wiehe K, Saunders KO, Pollara J, Vandergrift N, Parks R, Kim J, Michael NL, O'Connell RJ, Excler JL, Robb ML, Vasan S, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Nitayaphan S, Sinangil F, Tartaglia J, Phogat S, Kepler TB, Alam SM, Liao HX, Ferrari G, Seaman MS, Montefiori DC, Tomaras GD, Harrison SC, Haynes BF. Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial. PLoS Pathog. 2017 Feb 24;13(2):e1006182.

Karnasuta C, Akapirat S, Madnote S, Savadsuk H, Puangkaew J, Rittiroongrad S, Rerks-Ngarm S, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Tartaglia J, Sinangil F, Francis DP, Robb ML, de Souza MS, Michael NL, Excler JL, Kim JH, O'Connell RJ, Karasavvas N. Comparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination Regimens. AIDS Res Hum Retroviruses. 2017 May;33(5):410-423.

2016

Luo K, Liao HX, Zhang R, Easterhoff D, Wiehe K, Gurley TC, Armand LC, Allen AA, Von Holle TA, Marshall DJ, Whitesides JF, Pritchett J, Foulger A, Hernandez G, Parks R, Lloyd KE, Stolarchuk C, Sawant S, Peel J, Yates NL, Dunford E, Arora S, Wang A, Bowman CM, Sutherland LL, Scearce RM, Xia SM, Bonsignori M, Pollara J, Edwards RW, Santra S, Letvin NL, Tartaglia J, Francis D, Sinangil F, Lee C, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Michael NL, Kim JH, Alam SM, Vandergrift NA, Ferrari G, Montefiori DC, Tomaras GD, Haynes BF, Moody MA. Tissue memory B cell repertoire analysis after ALVAC/AIDSVAX B/E gp120 immunization of rhesus macaques. JCI Insight. 2016 Dec 8;1(20):e88522.

Astronomo RD, Santra S, Ballweber-Fleming L, Westerberg KG, Mach L, Hensley-McBain T, Sutherland L, Mildenberg B, Morton G, Yates NL, Mize GJ, Pollara J, Hladik F, Ochsenbauer C, Denny TN, Warrier R, Rerks-Ngarm S, Pitisuttithum P, Nitayapan S, Kaewkungwal J, Ferrari G, Shaw GM, Xia SM, Liao HX, Montefiori DC, Tomaras GD, Haynes BF, Juliana McElrath M. Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection. EBioMedicine. 2016 Dec;14:97-111

Pitisuttithum P, Bouckenooghe A. The first licensed dengue vaccine: an important tool for integrated preventive strategies against dengue virus infection. Expert Rev Vaccines. 2016 Jul;15(7):795-8.

Pitisuttithum P, Islam D, Chamnanchanunt S, Ruamsap N, Khantapura P, Kaewkungwal J, Kittitrakul C, Luvira V, Dhitavat J, Venkatesan MM, Mason CJ, Bodhidatta L. Clinical Trial of an Oral Live Shigella sonnei Vaccine Candidate, WRSS1, in Thai Adults. Clin Vaccine Immunol. 2016 Jul 5;23(7):564-75.

2015

baldwin KM, Ehrenberg PK, Geretz A, Prentice HA,Nitayaphan S, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, O’Connell RJ, Kim JH, Thomas R. HLA class ll diversity in HIV-1 uninfected individuals form the placebo arm of the RV144 Thai vaccine efficacy trial.Tissue Antigens 2015 Feb 85(2):117-26

Choi I, Chung AW, Suscovich TJ, Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, O'Connell RJ, Francis D, Robb ML, Michael NL, Kim JH, Alter G, Ackerman ME, Bailey-Kellogg C.Machine learning methods enable predictive modeling of antibody feature:function relationships in RV144 vaccinees. PLoS Comput Biol. 2015 Apr 11(4):e1004185.

Edlefsen PT, Rolland M, Hertz T, Tovanabutra S, Gartland AJ, deCamp AC, Magaret CA, Ahmed H, Gottardo R, Juraska M, McCoy C, Larsen BB, Sanders-Buell E, Carrico C, Menis S, Bose M; RV144 Sequencing Team, Arroyo MA, O'Connell RJ, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Rerks-Ngarm S, Robb ML, Kirys T, Georgiev IS, Kwong PD, Scheffler K, Pond SL, Carlson JM, Michael NL, Schief WR, Mullins JI, Kim JH, Gilbert PB.Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial. PLoS Comput Biol. 2015 Feb 11(2):e1003973.

Hadinegoro SR, Arredondo-García JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, Muhammad Ismail HI, Reynales H, Limkittikul K, Rivera-Medina DM, Tran HN, Bouckenooghe A, Chansinghakul D, Cortés M, Pitisuttithum P ,Fanouillere K, Forrat R, Frago C, Gailhardou S, Jackson N, Noriega F, Plennevaux E, Wartel TA, Zambrano B, Saville M; CYD-TDV Dengue Vaccine Working Group.Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease. N Engl J Med. 2015 Sep 24;373(13):1195-206.

Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, Moreira ED Jr, Ngan Y, Petersen LK, Lazcano-Ponce E, Pitisuttithum P, Restrepo JA, Stuart G, Woelber L, Yang YC, Cuzick J, Garland SM, Huh W, Kjaer SK, Bautista OM, Chan IS, Chen J, Gesser R, Moeller E, Ritter M, Vuocolo S, Luxembourg A; Broad Spectrum HPV Vaccine Study.A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015 Feb 372(8):711-23

Janes H, Herbeck JT, Tovanabutra S, Thomas R, Frahm N, Duerr A, Hural J, Corey L, Self SG, Buchbinder SP, McElrath MJ, O'Connell RJ, Paris RM, Rerks-Ngarm S, Nitayaphan S, Pitisuttihum P, Kaewkungwal J, Robb ML, Michael NL, Mullins JI, Kim JH, Gilbert PB, Rolland M.HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders. Nat Med. 2015 Oct (10):1139-41

Karasavvas N, Karnasuta C, de Souza MS, Inthawong D, Savadsuk H, Madnote S, Chantakulkij S, Rittiroongrad S, Nitayaphan S, Pitisuttithum P, Thongcharoen P, Siriyanon V, Andrews C, Barnett SW, Tartaglia J, Sinangil F, Francis DP, Robb M, Michael NL, Ngauy V, Paris RM, Excler DJ, Kim JH, O'Connell RJ. IgG Antibody Responses to Recombinant gp120 proteins, gp70V1/V2 Scaffolds and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials using Different Vaccine Regimens. AIDS Res Hum Retroviruses. 2015 Nov;31(11):1178-86.

Lin L, Finak G, Ushey K, Seshadri C, Hawn TR, Frahm N, Scriba TJ, Mahomed H, Hanekom W, Bart PA, Pantaleo G, Tomaras GD, Rerks-Ngarm S, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Michael NL, Kim JH, Robb ML, O'Connell RJ, Karasavvas N, Gilbert P, C De Rosa S, McElrath MJ, Gottardo R.COMPASS identifies T-cell subsets correlated with clinical outcomes. Nat Biotechnol. 2015 Jun;33(6):610-6.

Nicely NI, Wiehe K, Kepler TB, Jaeger FH, Dennison SM, Rerks-Ngarm S, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Robb ML, O'Connell RJ, Michael NL, Kim JH, Liao HX, Munir Alam S, Hwang KK, Bonsignori M, Haynes BF.Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee. EBioMedicine. 2015 Jul 2(7):713-22

Pitisuttithum P, Rerks-Ngarm S, Stablein D, Dawson P, Nitayaphan S, Kaewkungwal J, Michael NL, Kim JH, Robb ML, O'Connell RJ, Yoon IK, Fernandez S, Excler JL.Accuracy of Clinical Diagnosis of Dengue Episodes in the RV144 HIV Vaccine Efficacy Trial in Thailand. PLoS One. 2015 May 10(5):e0127998.

Prentice HA, Tomaras GD, Geraghty DE, Apps R, Fong Y, Ehrenberg PK, Rolland M, Kijak GH, Krebs SJ, Nelson W, DeCamp A, Shen X, Yates NL, Zolla-Pazner S, Nitayaphan S, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Ferrari G, McElrath MJ, Montefiori DC, Bailer RT, Koup RA, O'Connell RJ, Robb ML, Michael NL, Gilbert PB, Kim JH, Thomas R.HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition. Sci Transl Med. 2015 Jul 7(296):296ra112.

Pitisuttithum P, Velicer C, Luxembourg A. 9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV.Expert Review of Vaccines 2015 Nov 14(11):1405-19

Peachman KK, Karasavvas N, Chenine AL, McLinden R, Rerks-Ngarm S, Jaranit K, Nitayaphan S, Pitisuttithum P, Tovanabutra S, Zolla-Pazner S, Michael NL, Kim JH, Alving CR, Rao M.Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to α4β7 Integrin Receptor. PLoS One. 2015 Dec 1;10(12):e0143895.

Santra S, Tomaras GD, Warrier R, Nicely NI, Liao HX, Pollara J, Liu P, Alam SM, Zhang R, Cocklin SL, Shen X, Duffy R, Xia SM, Schutte RJ, Pemble Iv CW, Dennison SM, Li H, Chao A, Vidnovic K, Evans A, Klein K, Kumar A, Robinson J, Landucci G, Forthal DN, Montefiori DC, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Robb ML, Michael NL, Kim JH, Soderberg KA, Giorgi EE, Blair L, Korber BT, Moog C, Shattock RJ, Letvin NL, Schmitz JE, Moody MA, Gao F, Ferrari G, Shaw GM, Haynes BF. Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. PLoS Pathog. 2015 Aug 3;11(8):e1005042.

Van Damme P, Olsson SE, Block S, Castellsague X, Gray GE, Herrera T, Huang LM, Kim DS, Pitisuttithum P, Chen J, Christiano S, Maansson R, Moeller E, Sun X, Vuocolo S, Luxembourg A.Immunogenicity and Safety of a 9-Valent HPV Vaccine. Pediatrics. 2015 Jul;136(1):e28-39

Vasan S, Rerks-Ngarm S, Gilbert P, Haynes B, Nitayapan S, Pitisuttihum P, Kaewkungwal J, Excler JL, Robb M, Michael N, Kim J, O'Connell R.Letter to the Editor on: The RV144 vaccine regimen was not associated with enhancement of infection. in: Hum Vaccin Immunother. Apr 2015;11(4):1036-7

Worasathit R, Wattana W, Okanurak K, Songthap A, Dhitavat J, Pitisuttithum P.Health education and factors influencing acceptance of and willingness to pay for influenza vaccination among older adults. BMC Geriatr. 2015 Oct 15(1):136.

2014

Ana-Sosa-Batiz F*, Johnston AP, Liu H, Center RJ, Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Kim JH, Michael NL, Kelleher AD, Stratov I, Kent SJ, Kramski M. HIV-specific antibody-dependent phagocytosis matures during HIV infection.Immunology and Cell Biology. 2014 Sep 92(8): 679-87

Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua MN, Luong CQ, Rusmil K, Wirawan DN, Nallusamy R, Pitisuttithum P, Thisyakorn U, Yoon IK, van der Vliet D*, Langevin E, Laot T, Hutagalung Y, Frago C, Boaz M, Wartel TA, Tornieporth NG, Saville M, Bouckenooghe A. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 2014 Oct 384(9951): 1358-65

Chung AW, Ghebremichael M, Robinson H, Brown E, Choi I, Lane S, Dugast AS, Schoen MK, Rolland M, Suscovich TJ, Mahan AE, Liao L, Streeck H, Andrews C, Rerks-Ngarm S, Nitayaphan S, de Souza MS, Kaewkungwal J, Pitisuttithum P, Francis D, Michael NL, Kim JH, Bailey-Kellogg C, Ackerman ME, Alter G*. Polyfunctional Fc-Effector Profiles Mediated by IgG Subclass Selection Distinguish RV144 and VAX003. Vaccines Science Translational Medicine. 2014 Mar 6(228):228ra8

Dennison SM, Anasti KM, Jaeger FH, Stewart SM, Pollara J, Liu P, Kunz EL, Zhang R, Vandergrift N, Permar S, Ferrari G, Tomaras GD, Bonsignori M, Michael NL, Kim JH, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Liao HX, Haynes BF, Alam SM*. Vaccine-Induced HIV-1 Envelope gp120 Constant Region 1-Specific Antibodies Expose a CD4-Inducible Epitope and Block the Interaction of HIV-1 gp140 with Galactosylceramide. Journal of Virology 2014 Aug 88(16): 9406-17

Dennison SM, Anasti KM, Jaeger FH, Stewart SM, Pollara J, Liu P, Kunz EL, Zhang R, Vandergrift N, Permar S, Ferrari G, Tomaras GD, Bonsignori M, Michael NL, Kim JH, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Liao HX, Haynes BF, Alam SM*. Vaccine-Induced HIV-1 Envelope gp120 Constant Region 1-Specific Antibodies Expose a CD4-Inducible Epitope and Block the Interaction of HIV-1 gp140 with Galactosylceramide. Journal of Virology 2014 Aug 88(16): 9406-17

Joura EA*, Ault KA, Bosch FX, Brown D, Cuzick J, Ferris D, Garland SM, Giuliano AR, Hernandez-Avila M, Huh W, Iversen OE, Kjaer SK, Luna J, Miller D, Monsonego J, Munoz N, Myers E, Paavonen J, Pitisuttithum P, Steben M, Wheeler CM, Perez G, Saah A, Luxembourg A, Sings HL, Velicer C. Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease. Cancer Epidemiology Biomarkers and Prevention 2014 Oct 23(10): 1997-2008

Khowsroy K, Dhitavat J*, Sabmee Y, Laowarakul P, Wattanakitwichai J, Auetian J, Lothong K, Boondao R, Maythaarttaphong S, Yaemwong S, Excler JL, Rerks-Ngarm S, Pitisuttithum P. Expectation of Volunteers Towards the Vaccine Efficacy of the Prime-Boost HIV Vaccine Phase III Trial During Unblinding. AIDS Research and Human Retroviruses. 2014 Nov 30(11): 1041-5

Li SS*, Gilbert PB*, Tomaras GD, Kijak G, Ferrari G, Thomas R, Pyo CW, Zolla-Pazner S, Montefiori D, Liao HX, Nabel G, Pinter A, Evans DT, Gottardo R, Dai JY, Janes H, Morris D, Fong Y, Edlefsen PT, Li F, Frahm N, Alpert MD, Prentice H, Rerks-Ngarm S, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Robb ML, O'Connell RJ, Haynes BF, Michael NL, Kim JH, McElrath MJ, Geraghty DE. FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. Journal of Clinical Investigation. 2014 Sep 124(9): 3879-90

Penezina O, Krueger NX, Rodriguez-Chavez IR, Busch MP, Hural J, Kim JH, O'Connell RJ, Hunter E, Aboud S, Higgins K, Kovalenko V, Clapham D, Crane D, Levin AE*, Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Andrews C, Kilembe W, Karita E, Allen S, Munseri P, Joachim A, Bakari M, Mhalu F, Aris E, Nilsson C, Biberfeld G, Robb M, Marovich M, Sandstrom E. Performance of a redesigned HIV Selectest enzyme-linked immunosorbent assay optimized to minimize vaccine-induced seropositivity in HIV vaccine trial participants. Clinical and Vaccine Immunology 2014 Mar 21(3): 391-8

Pollara J, Bonsignori M, Moody MA, Liu PH, Alam SM, Hwang KK, Gurley TC, Kozink DM, Armand LC, Marshall DJ, Whitesides JF, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Robb ML, O'Connell RJ, Kim JH, Michael NL, Montefiori DC, Tomaras GD, Liao HX, Haynes BF, Ferrari G*. HIV-1 Vaccine-Induced C1 and V2 Env-Specific Antibodies Synergize for Increased Antiviral Activities. Journal of Virology. 2014 Jul 88(14): 7715-26

Prentice HA, Ehrenberg PK, Baldwin KM, Geretz A, Andrews C, Nitayaphan S, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, O'Connell RJ, Robb ML, Kim JH, Michael NL, Thomas R*. HLA class I, KIR, and genome-wide SNP diversity in the RV144 Thai phase 3 HIV vaccine clinical trial. Immunogenetics 2014 May 66(5):299-310

Rid A*, Saxena A, Baqui AH, Bhan A, Bines J, Bouesseau MC, Caplan A, Colgrove J, Dhai A, Gomez-Diaz R, Green SK, Kang G, Lagos R, Loh P, London AJ, Mulholland K, Neels P, Pitisuttithum P, Sarr SC, Selgelid M, Sheehan M, Smith PG. Placebo use in vaccine trials: Recommendations of a WHO expert panel. Vaccine 2014 Aug 32(37): 4708-12

Stieh DJ, King DF, Klein K, Liu P, Shen X, Hwang KK, Ferrari G, Montefiori DC, Haynes B, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Michael NL, Robb ML, Kim JH, Denny TN, Tomaras GD, Shattock RJ*. Aggregate complexes of HIV-1 induced by multimeric antibodies. Retrovirology. 2014 Oct 11(1):78

Thanachartwet V, Desakorn V, Duangrithi D, Chunpongthong P, Phojanamongkolkij K, Jitruckthai P, Kasetjaroen Y, Pitisuttithum P*. Comparison of clinical and laboratory findings between those with pulmonary tuberculosis and those with nontuberculous mycobacterial lung disease. Southeast Asian Journal of Tropical Medicine and Public Health. 2014 Jan 45(1):85-94

Wiehe K*, Easterhoff D, Luo K, Nicely NI, Bradley T, Jaeger FH, Dennison SM, Zhang R, Lloyd KE, Stolarchuk C, Parks R, Sutherland LL, Scearce RM, Morris L, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Sinangil F, Phogat S, Michael NL, Kim JH, Kelsoe G, Montefiori DC, Tomaras GD, Bonsignori M, Santra S, Kepler TB, Alam S, Moody MA, Liao HX, Haynes BF. Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved. Immunity 2014 Dec 41(6): 909-18

Yates NL, Liao HX, Fong YI, deCamp A, Vandergrift NA, Williams WT, Alam SM, Ferrari G, Yang ZY, Seaton KE, Berman PW, Alpert MD, Evans DT, O'Connell RJ, Francis D, Sinangil F, Lee C, Nitayaphan S, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Tartaglia J, Pinter A, Zolla-Pazner S, Gilbert PB, Nabel GJ, Michael NL, Kim JH, Montefiori DC, Haynes BF, Tomaras GD*. Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination. Science Translational Medicine. 2014 Mar 6(228): 228ra39

Yeekian C, Geratikornsupak N, Chumpongthong P, Tongsiri S, Dhitavat J, Phonrat B, Pitisuttithum P*. Medical and economic burden of chronic hepatitis B patients at Queen Savang Vadhana Memorial Hospital. Journal of the Medical Association of Thailand. 2014 Apr 97(4): 447-55

Zolla-Pazner S*, deCamp A, Gilbert PB, Williams C, Yates NL, Williams WT, Howington R, Fong Y, Morris DE, Soderberg KA, Irene C, Reichman C, Pinter A, Parks R, Pitisuttithum P, Kaewkungwal J, Rerks-Ngarm S, Nitayaphan S, Andrews C, O'Connell RJ, Yang ZY, Nabel GJ, Kim JH, Michael NL, Montefiori DC, Liao HX, Haynes BF, Tomaras GD. Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. PLoS One 2014 Feb 9(2): e87572

พรรณี ปิติสุทธิธรรม. วัคซีนป้องกันโรคเอดส์. ใน: โอฬาร พรหมาลิขิต, อัจฉรา ตั้งสถาพรพงษ์ และ อุษา ทิสยากร, บรรณาธิการ. วัคซีน. พิมพ์ครั้งที่ 2. กรุงเทพฯ: นพชัยการพิมพ์; 2558. หน้า 511-523.

2013

2012

2011

Alpert MD, Harvey JD, Neidermyer WJ, Huang Y, Morris D, Harris L, Gao H, Montefiori DC, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Michael NL, Kim J, Evans DT. ADCC titers to HIV-infected cells are detectable in the majority of vaccine recipients in the RV144 trial (Oral Presentation). AIDS VACCINE 2011, Bangkok, Thailand, Sep 12-15, 2011 p.76.

Aunhachoke K, Bussaratid V, Chirachanakul P, Chua-Intra B, Dhitavat J, Jaisathaporn K, Kaewkungwal J, Kampirapap K, Khuhaprema T, Pairayayutakul K, Pitisuttithum P, Sindhvananda J, Thaipisuttikul Y; for the Thai Herpes Zoster Study Group. Measuring herpes zoster, zoster-associated pain, post-herpetic neuralgia-associated loss of quality of life, and healthcare utilization and costs in Thailand. Int J Dermatol. 2011 Apr;50(4):428-435.

Billings EA, Karasavvas N, De Souza MS, Currier J, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Gilbert PB, Tomaras GD, Zolla-Pazner SB, Haynes BF, Nichael NL, Rerks-Ngarm S, Kim J, Rao M. Surface Plasmon resonance analysis of anti-gp120 V2-specific IgG antibodies generated in the RV144 Thai trial (Oral Presentation). AIDS VACCINE 2011, Bangkok, Thailand, Sep 12-15, 2011 p.77.

Castellsagué X, Muñoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K, Luna J, Myers E, Mallary S, Bautista OM, Bryan J, Vuocolo S, Haupt RM, Saah A. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer. 2011 May 31.

Chunpongthong P, Win Ko Ko Z, Yeekian C, Luvira V, Pitisuttithum P. Outcomes of antituberculosis treatments at 18 months follow-up in TB-HIV co-infected patients on ART: a retrospective review of 166 cases. J Med Assoc Thai 2011; 94 (6): 664-670.

Desakorn V, Karmacharya BM, Thanachartwet V, Kyaw NL, Tansuphasawadikul S, Sahassananda D, Dhitavat J, Maek-a-nantawat W, Pitisuttithum P. Effectiveness of fixed-dose combination stavudine, lamivudine and nevirapine (GPO-VIR) for treatment of naïve HIV patients in Thailand: a 3-year follow-up. Southeast Asian J Trop Med Public Health. 2011 Nov;42(6):1414-1422.

Karasavvas N, Billings E, Rao M, Currier J, Michael NL, Rerks-Ngarm S, Pitisuttithum P, Kaewkungwal J, Ngauy V, Nitayaphan S, Madnote S, Arworn D, Kim J, De Souza M. The Thai Phase Iii clinical trial (RV144) induces the generation of antibodies that target a conserved region within the V2 loop of gp120 (Oral Presentation). AIDS VACCINE 2011, Bangkok, Thailand, Sep 12-15, 2011 p.71.

Larsen RA, Bauer M, Pitisuttithum P, Sanchez A, Tansuphaswadikul S, Wuthiekanun V, Peacock SJ, Simpson AJ, Fothergill AW, Rinaldi MG, Bustamante B, Thomas AM, Altomstone R, Day NP, White NJ. CORRELATION OF SUSCEPTIBILITY TESTING OF C. NEOFORMANS TO AMPHOTERICIN B WITH CLINICAL OUTCOME. Antimicrob Agents Chemother. 2011 Sep 26.

Pitisuttithum P, Rerks-Ngarm S, Bussaratid V, Dhitavat J, Maekanantawat W, Pungpak S, Suntharasamai P, Vanijanonta S, Nitayapan S, Kaewkungwal J, Benenson M, Morgan P, O'Connell RJ, Berenberg J, Gurunathan S, Francis DP, Paris R, Chiu J, Stablein D, Michael NL, Excler JL, Robb ML, Kim JH. Safety and Reactogenicity of Canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E Vaccination in an Efficacy Trial in Thailand. PLoS One. 2011;6(12): e27837.

Pitisuttithum P, Rerks-Ngarm S, Bussaratid V, Dhitavat J, Maekanantawat W, Pungpak S, Suntharasamai P, Vanijanonta S, Nitayaphan S, Kaewkungwal J, Chunsuttiwat, S, Premsri N, Benenson M, Morgan P, Berenberg J, Gurunathan S, Francis DP, Chiu J, Excler J, Robb ML, Stablein D, Michael NL, Kim J. Safety and Reactogenicity of ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E Prime-Boost vaccination regimen in a community-based efficacy trial (Abstract). AIDS VACCINE 2011, Bangkok, Thailand, Sep 12-15, 2011 p.156.

Pitisuttithum P, Rerks-Ngarm S, Chiu J, Kim J, Benenson M, Kent SJ, Tamashiro H, Manrique A, Bernstein A, Goyal R, Ditangco RA, Cooper DA, Osmanov S, Mathieson B, Sandstrom E, Esparza J, Hoff R, Shao Y for the AIDS Vaccine for Asia Network. Accelerating the development of an AIDS Vaccine: The AIDS Vaccine for Asia Network (AVAN). Southeast Asian J Trop Med Public Health. 2011 Sep;42(5):1130-1146.

Pitisuttithum P. Thailand’s contribution to HIV vaccine research and development (Abstract). AIDS VACCINE 2011, Bangkok, Thailand, Sep 12-15, 2011 p.21.

The Ministry of Public Health - Thai AIDS Vaccine Evaluation Group (MOPH-TAVEG). Screening and evaluation of potential volunteers for a phase III trial in Thailand of a candidate preventive HIV vaccine (RV148). Vaccine 29 (2011) 4285–4292.

2010

Aramaki M, Silachamroon U, Desakorn V, Maek-A-nantawat W, Waiwaruwut J, Jutiwarakun K, Kim JH, Pitisuttithum P. Immune reconstitution inflammatory syndrome in adult human immunodeficiency virus-infected patients in Thailand. Southeast Asian J Trop Med Public Health. 2010 Jan;41(1):138-45.

Baldwin K, Cervenka T, De Souza MS, Paris R, Koehler R, Thongcharoen P, Pitisuttithum P, Nitayaphan S, Suriyanon V, Robb M, Michael N, Kim J, Kijak G, and the TAVEG. Genetics of Fc Gamma Receptors IIa and IIIa in vaccine trial reagents to support the study of immune correlates in RV144 (Abstract). AIDS VACCINE 2010, Atlanta, USA, Sep 28-Oct 1, 2010 p.158

Cervenka T, Baldwin K, De Souza MS, Paris R, Koehler R, Thongcharoen P, Pitisuttithum P, Nitayaphan S, Suriyanon V, Robb M, Michael N, Kim J, Kijak G, and the TAVEG. Feasibility of high-throughout and low-cost high-resolution class I HLA typing of HIV vaccine trial cohorts in Southeast Asia (Abstract). AIDS VACCINE 2010, Atlanta, USA, Sep 28-Oct 1, 2010 p.157

Jayathunge MP, Bowanwatanuwong C, Maek-A-nantawat W, Pitisuttithum P. Psychosocial burden of abnormal pap smears among HIV-infected women at Chon Buri hospital, Thailand. Southeast Asian J Trop Med Public Health. 2010 Jan;41(1):224-34.

Kaewkungwal J, Pitisuttithum P, Nitayaphan S, Stablein D, Chiu J, Benenson M, Kim J, Robb M, Michael N, Rerks-Ngarm S. Exploratory Age-stratified analysis of risk-taking behaviors and trial participation outcomes in the Thai phase III HIV vaccine trial (Oral Presentation). AIDS VACCINE 2010, Atlanta, USA, Sep 28-Oct 1, 2010 p.66

Kent SJ, Cooper DA, Chhi Vun M, Shao Y, Zhang L, Ganguly N, Bela B, Tamashiro H, Ditangco R, Rerks-Ngarm S, Pitisuttithum P, Van Kinh N, Bernstein A, Osmanov S; AIDS Vaccine for Asia Network investigators and supporters. AIDS vaccine for Asia Network (AVAN): expanding the regional role in developing HIV vaccines. PLoS Med. 2010 Sep 21;7(9):e1000331.

Martin M, Vanichseni S, Suntharasamai P, Mock PA, van Griensven F, Pitisuttithum P, Tappero JW, Chiamwongpaet S, Sangkum U, Kitayaporn D, Gurwith M, Choopanya K; for the Bangkok Vaccine Evaluation Group. Drug use and the risk of HIV infection amongst injection drug users participating in an HIV vaccine trial in Bangkok, 1999-2003. Int J Drug Policy. 2010 Jul;21(4):296-301

Mast TC, Kierstead L, Gupta SB, Nikas AA, Kallas EG, Novitsky V, Mbewe B, Pitisuttithum P, Schechter M, Vardas E, Wolfe ND, Aste-Amezaga M, Casimiro DR, Coplan P, Straus WL, Shiver JW. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine. 2010 Jan 22;28(4):950-7.

Nicholson O, Dicandilo F, Kublin J, Sun X, Quirk E, Miller M, Gray G, Pape J, Robertson MN, Mehrotra DV, Self S, Turner K, Sanchez J, Pitisuttithum P, Duerr A, Dubey S, Kierstead L, Casimiro D, Hammer SM; for the Merck V520-018/HIV Vaccine Trials Network 050 Study Team. Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults. AIDS Res Hum Retroviruses. 2010 Nov 23.

Pitisuttithum P, Choopanya K, Rerk-Ngnam S. HIV-vaccine research and development in Thailand: evolution and challenges. Vaccine. 2010 May 26;28 Suppl 2:B45-9.

Pitisuttithum P, Rerks-Ngarm S, Bussaratid V, Dhitavat J, Maek-a-nantawat W, Pungpak S, Suntharasamai P, Vanijanonta S, Nitayaphan S, Kaewkungwal J, Benenson MW, Chiu J, Robb ML, Gurunathan S, Francis D, Stablein DM, Kim J. Safety profiles of ALVAC HIV and AIDSVAX vaccines in the Phase III community based trial in Thailand (Abstract). AIDS VACCINE 2010, Atlanta, USA, Sep 28-Oct 1, 2010 p.193

Rerks-Ngarm S, Pitisuttithum P, Ganguly N, Zhang L, Tamashiro H, Cooper DA, Vun MC, Bela B, Ditangco R, Van KN, Bernstein A, Osmanov S, Mathieson B, Kent SJ, Shao Y. Defining the objectives of the AIDS vaccine for Asia network: report of the WHO-UNAIDS/Global HIV vaccine enterprise regional consultation on expanding. Current Opinion in HIV & AIDS. 5(5):435-452, September 2010.

Rerks-Ngarm S, Premsri N, Namwat C, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Kingko P, Jirasethasiri M, Paris R, Chiu J, Kim J, Khamboonruang C, Thongchaeon P, Kunasol P. Community engagement; experience from the Thai Phase III Prime-Boost HIV vaccine trial, RV144 (Abstract). AIDS VACCINE 2010, Atlanta, USA, Sep 28-Oct 1, 2010 p.204

2009

2008

Chamnachanan S, Tu A K, Tansuphasawadiku S, Phonrat B, Pitisuttithum P, Dhitavat J. Pulmonary tuberculosis treatment outcomes in HIV infected patients on antiretroviral therapy. International journal of infectious diseases, 2008 Jun 2; 12: s23-s23,52 suppl.

Excler JL, Pitisuttithum P, Rerks-Ngarm S, Shao Y, Zhang L, Tamashiro H, et al. Expanding Research Capacity and Accelerating AIDS Vaccine Development in Asia. Southeast Asian J Trop Med Public Health 2008; 39(4):766-784

J. Kaewkungwal, P. Pitisuttithum, S. Nitayapan, C. Khamboonruang, P. Thongchareon, P. Kunasol, R. Paris, M. Benenson, J. Kim, S Rerks-Ngarm, MoPH TAVEG. Monitoring selection bias in phase III vaccine trail of ALVAC vaccine priming, AIDSVAX vaccine boosting in Thailand (Abstract). AIDS 2008, Mexico, August 3 - 8, 2008. Abstract Book vol. 2, p.118-119.

Kaewkungwal J, Pitisuttithum P, Nitayapan S, Khamboonruang C, Thongchareon P, Kunasol P, Paris R, Benenson M, Kim J, Rerks-Ngarm S, MoPH TAVEG. Monitoring selection bias in phase III vaccine trail of ALVAC vaccine priming, AIDSVAX vaccine boosting in Thailand (Abstract). AIDS 2008, Mexico, August 3 - 8, 2008. Abstract Book vol. 2, p.118-119

Liangthorachon C, Khowsroy K, Boondao R, Lothong K, Sabmee Y, Rerks-Ngarm S, Kim JH, Pitisuttithum P. Knowledge and Expecatation of Participants in the Phase III HIV Vaccine Trial in Preparation for the Results of the Efficacy Interim Analysis (Abstract). AIDS VACCINE 2008, Cape Town, South Africa, October 13-16, 2008 p.174

Maek-a-nantawat W, Phonrat B, Dhitavat J, Naksrisook S, Muanaum R, Ngamdee V, Pitisuttithum P. Safety and Efficacy of CKBM-A01, a Chinese Herbal Medicine, Among Asymptomatic HIV Patients. Southeast Asian J Trop Med Public Health 2008 (in press).

Naksrisook S, Phonrat B, Ruengkris T, Intalapaporn K, Pitisuttithum P, Jirakorbchaipong P. Psychosocial Burden of Abnormal Pap in Thailand (Poster Presentation). Pharmacoeconomics and Outcomes Research in Thailand: A Stepping Stone Toward National Drug Policy, Bangkok, Thailand, May 12-13, 2008

Pitisuttithum P. AIDS Vaccine Research in Thailand (Abstract). 21st Joint Meeting of the AIDS Panels, Tokyo, Japan, September 10-12, 2008.

Pitisuttithum P. Clinical Trial and Principal of ICH GCP (Presentation). CU Cooperative Study Group, Maehongson, Thailand, January 11-13, 2008

Pitisuttithum P. Herpes Zoster and post herpetic neuralgia-the Thailand perspective (Presentation). 13th International Congress on Infectious Diseases, Kuala Lumpur, Malaysia, June 19-22, 2008.

Pitisuttithum P. HIV vaccine research in Thailand: lessons learned. Expert Review of Vaccines. 2008 Apr; 7(3): 311-7

Pitisuttithum P AIDS Vaccines Research Project. Medical Time 2008; 9(213): 50-52

Pitisuttithum P, Rerks-Ngarm S, Bussaratid V, Dhitavat J, Maekanantawat W, Pungpak S, Suntharasamai P, Vanijanonta S, Benenson MW, Kim JH. Retention Activities of Clinical Sites to Ensure Compliance among Participants in the Phase III Community Trial in Thailand (Abstract). AIDS VACCINE 2008, Cape Town, South Africa, October 13-16, 2008 p.173

Pitisuttithum P, Rerks-Ngarm S, Kaewkungwal J, Nitayaphan S, Benenson M, Paris R, Michael N, Kim J, Khamboonruang C, Kunasol P. The Follow-up Phase of the Phase III Community Trial: Current Activities (Oral Presentation). AIDS VACCINE 2008, Cape Town, South Africa, October 13-16, 2008 p.64

Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kim J, Kaewkungwal J, Gurunathan S, Gurwith M, Micahel N, Khamboonruang C, Thongcharoen P, Kunasol P. Phase III Trial of HIV Prime-Boost Vaccine Combination in Thailand: Follow up Phase (Abstract). AIDS VACCINE 2008, Cape Town, South Africa, October 13-16, 2008 p.176

2007

Ackland J, Allen S, Barth-Jones D, Birx D, Chomba E, Churchyard G, Duerr A, Jin S, Johnston M, Fast PE, Fix A, Foulkes M, Follmann D, Hutubessy R, Malone S, Gray R, Indrayan A, Levin J, Mathieson BJ, Mastro TD, McNeil J, Osmanov S, Pitisuttithum P, et al. Executive summary and recommendations from the WHO/UNAIDS/IAVI expert group consultation on 'Phase IIB-TOC trials as a novel strategy for evaluation of preventive HIV vaccines'. AIDS 2007; 21(4):539-46.

Hammer S, Miller M, Pape J, Pitisuttithum P, Suriyanon V, Nitayaphan S, Sanchez J, Kallas E, Harro C, Gray G, Cadinali M, Turner K, Sun X, Mehrotra D, Quirk E. Safety and immunogenicity of the MRKAd5 gag HIV-1 vaccine in a worldwide phase I study of healthy adults (Merck V520-018/HVTN 050) (Abstract). AIDS VACCINE 2007, Seattle, USA, August 20-23, 2007 p.59

Maek-A-Nantawat W, Tansuphaswadikul S, Aung S, Phonrat B, Kaewkungwal J, Pitisuttithum P. Predisposing factors for nevirapine toxicity among AIDS patients with low baseline CD4 count. Allergy 2007; 62: 160.

Namwat C, Morgan P, Premsri N, Debyasuvarn T, Pitisuttithum P, Bussaratid V, Benenson M, Kim JH. Social Impact of participation in a phase III HIV vaccine trial in Thailand (Abstract). AIDS VACCINE 2007, Seattle, USA, August 20-23, 2007 p.105

Osmanov S, Ackland J, Allen S, Barth-Jones D, Birx D, Chomba E, Churchyard G, Duerr A, Jin SG, Johnston M, Fast PE, Fix A, Foulkes M, Follmann D, Hutubessy R, Malone S, Gray R, Indrayan A, Levin J, Mathieson BJ, Mastro TD, McNeil J, Pitisuttithum P, et al. Executive summary and recommendations from the WHO/UNAIDS/IAVI expert group consultation on 'Phase IIB-TOC trials as a novel strategy for evaluation of preventive HIV vaccines', 31 January-2 February 2006, IAVI, New York , USA . Aids2007; 21(4):539-46.

Paris RM, Bejrachandra S, Thongcharoen P, Nitayaphan S, Suriyanon V, Pitisuttithum P, Sambor A, Barnett S, Gurunathan S, Gurwith M, Kim S, MS de Souza, Polonis VR, Kim JH. HLA Class II alleles and neutralizing antibody responses to HIV-1 protein subunit boosting in a Thai population (Abstract). AIDS VACCINE 2007, Seattle, USA, August 20-23, 2007 p.135

Pitisuttithum P, Choopanya K, Bussaratid V, Vanichseni S, Griensven FV, Phonrat B, Martin M, Vimutsunthorn E, Sangkum U, Kitayaporn D, Tappero JW, Heyward W, Francis D. Social Harms in Injecting Drug Users Participating in the First Phase III HIV Vaccine Trial in Thailand. J Med Assoc Thai 2007; 90 (11): 2441-2448

Pitisuttithum P, Rerks-Ngarm S, Kaewkungwal J, Nitayaphan S, Khamboonruang C, Kunasol P, Benenson M, Kim J. Women participation in the phase III efficacy trial of ALVAC HIV-1 vaccine priming, AIDSVAX vaccine boosting in Thailand (Abstract). AIDS VACCINE 2007, Seattle, USA, August 20-23, 2007 p.92

Pitisuttithum P. Thailand’s eExperiences in Conducting HPV Vaccine Trials and HPV Vaccine Update (Abstract). National Cancer Conference, Bangkok, Thailand, December 12-14, 2007 p.47

Premsri N, Namwat C, Rerks-Ngarm S, Kunasol P, Khamboonreaung C, Chunsuttiwat S, Wattana S, Wiriyakijja W, Kim JH, Benenson MW, Pitisuttithum P, Nittayaphan S. Integration of community engagement activities support the prime-boost phase III HIV vaccine trial in Thailand (Abstract). AIDS VACCINE 2007, Seattle, USA, August 20-23, 2007 p.85

Rerks-Ngarm S, Chunsuttiwat S, Pitisuttithum P, Nittayaphan S, Kaewkungwal J, Kim JH, Wattana S, Wiriyakijja W, Thongchareon P, Kunasol P, Khamboonreaung C. Thai Prime-boost HIV vaccine phase III trial: update 2007 (Abstract). AIDS VACCINE 2007, Seattle, USA, August 20-23, 2007 p.102

Saito W, Pitisuttithum P, Tansuphasawadikul S, Dhitivat J, Phonrat B, Chamnachanan S, Kim J. Outcome of Tuberculosis in Advanced HIV-Infected Patients on Antiretroviral Therapy (Abstract). IAS 2007, Sydney, Australia, July 22-25, 2007.

Tansuphaswadikul S, Aung SE, Phonrat B, Kaewkungwal J, Pitisuttithum P, Maek-a-nantawat W. Predisposing factors for nevirapine toxicity among AIDS patients with low baseline CD4 count. Asian Pac J Allergy Immunol. 2007 Jun-Sep;25(2-3):147-54.

Tansuphasawadikul S, Saito W, Kim J, Phonrat B, Dhitivat J, Chamnachanan S, Pitisuttithum P. Outcomes in HIV-Infected Patients on Antiretroviral Therapy with Tuberculosis. Southeast Asian J Trop Med Public Health 2007; 38(6):1053-1060

2006

Getahun A, Tansuphasawadikul S, Desakorn V, Dhitavat J, Pitisuttithum P. Efficacy and safety of generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-vir) in advanced HIV infection. J Med Assoc Thai. 2006 Sep;89(9):1472-8.

Gupta SB, Mast CT, Wolfe ND, Novitsky V, Dubey SA, Kallas EG, Schechter M, Mbewe B, Vardas E, Pitisuttithum P, Burke D, Freed D, Mogg R, Coplan PM Condra JH, Long RS, Anderson K, Casimiro DR, Shiver JW, Straus WL. Cross-clade reactivity of HIV-1-specific T-cell responses in HIV-1-infected individuals from Botswana and Cameroon. J Acquir Immune Defic Syndr. 2006; 42(2):135-9

Pitisuttithum P. Chapter 3 HIV Vaccine Research in Thailand National Perspective: Overview of HIV Vaccine Research in Thailand. In : Pitisuttithum P, Francis DP, Esparza J, Thongcharoen P, eds. HIV Vaccine Research and Development in Thailand. Bangkok:Amarin Printing and Publishing Public Company; 2006:83-92.

Pitisuttithum P, Francis DP, Esaparza J, Thongcharoen P. Chapter 8 Epilogue: Lessons Learnt. In : Pitisuttithum P, Francis DP, Esparza J, Thongcharoen P, eds. HIV Vaccine Research and Development in Thailand. Bangkok: Amarin Printing and Publishing Public Company; 2006:337-342.

Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, Hu D, Tappero JW, Choopanya K. Randomized, Double-Blind, Placebo-Controlled Efficacy Trial of a Bivalent Recombinant Glycoprotein 120 HIV-1 Vaccine among Injection Drug Users in Bangkok, Thailand. J Infect Dis. 2006 Dec 15; 194(12):1661-1671.

Pitisuttithum P, Migasena S, Singhasivanon P. Chapter 4 Phase I/II HIV Vaccine Trials in Thailand: The Vaccine Trial Center, Faculty of Tropical Medecine, Mahidol University. In : Pitisuttithum P, Francis DP, Esparza J, Thongcharoen P, eds. HIV Vaccine Research and Development in Thailand. Bangkok: Amarin Printing and Publishing Public Company; 2006: 131-150.

Pitisuttithum P, Vanichseni S, Kitayaporn D, Choopanya K. Chapter 7 Conducting Phase III Trials of Candidate HIV Vaccines:Phase III Efficacy Trial of Bivalent B/E rgp 120 HIV Vaccine (AIDSVAX® B/E) in Bangkok. In: Pitisutthithum P, Francis DP, Esparza J, Thongcaroen P, eds, HIV Vaccine Research and Development in Thailand. Bangkok: Amarin Printing and Publishing Public Company; 2006:275-290.

Raad II, Graybill JR, Bustamante AB, Cornely OA, Gaona-Flores V, Afif C, Graham DR, Greenberg RN, Hadley S, Langston A, Negroni R, Perfect JR, Pitisuttithum P, Restrepo A, Schiller G, Pedicone L, Ullmann AJ. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis. 2006; 42(12):1726-34

Rerks-Ngam S, Pitisuttithum P, Kitayaporn D, et al. Chapter 7 Conducting Phase III Trials of Candidate HIV Vaccines:The Rayong-Chonburi Community Phase III HIV Vaccine Trial. In : Pitisuttithum P, Francis DP, Esparza J, Thongcharoen P, eds. HIV Vaccine Research and Development in Thailand. Bangkok: Amarin Printing and Publishing Public Company; 2006:293-305.

Tansuphaswadikul S, Maek-a-nantawat W, Phonrat B, Boonpok L, Getahun A, Pitisuttithum P. Comparison of One Week with Two Week Regimens of Amphotericine B Both followed by Fluconazole in the Treatment of Cryptococcal Meningitis among AIDS Patients. J Med Assoc Thai 2006; 89(10):1677-1685

2005

2001

Meak-A-Nantawat W, Pitisuttithum P, Phonrat B, Budsaratid V, Naksrisook S, Peonim W, Thantamnu N and Muanom R, Knowledge behavioral risk and psychological assessment of Thai volunteers participating in phase I/II HIV/AIDS vaccine trials. 6th International Congress on AIDS in Asia and the Pacific Melbourne, Australia, October 5 – 10, 2001

Pitisuttithum P, Choopanya K, Phonrat B, Vanichseni S, Sangkum U, Heyward W, Gee C. for the Bangkok Vaccine Evaluation Group. The Conduct of Good Clinical Practices (GCP) in the First HIV-1 Vaccine Efficacy Trial in a Developing Country – Bangkok, Thailand (Abstract). 6th International Congress on AIDS in Asia and the Pacific, Melbourne, Australia, Oct. 5-10, 2001

Pitisuttithum P, Cohen M.B., Phonrat B., Suthisarnsuntorn U., Bussaratid V., Desakorn V., Phumratanaprapin W, et al. A human volunteer challenge model using frozen bacteria of the new epidemic serotype, V. cholerae O139 in Thai volunteers. Vaccine 2001; 20 (5-6): 920-925.

Pitisuttithum P, Nitayaphan S, Phonrat B, Heyward W, Gurunathan S, Kim J, Brown A and the Thai AIDS Vaccine Evaluation Group. Safety of Live Recombinant ALVAC – HIV (vCP1521) Priming with AIDSVAXTM B/E Boosting in Thai HIV – 1 negative Participants: Preliminary Results (Abstract). 6th International Congress on AIDS in Asia and the Pacific, Melbourne, Australia , October 5 – 10 , 2001

Pitisuttithum P, Tansuphasawadikul S, Simpson AJ, Howe PA, White NJ. A prospective study of AIDS-associated cryptococcal meningitis in Thailand: Treated with high-dose amphotericin B. J Infect 2001; 43:226-33.

Pitisuttithum P, The Bangkok Vaccine Evaluation Group. Thailand‘s Success in Moving to the First Phase III HIV Vaccine Efficacy Trial in a Developing Country (Abstract). AIDS VACCINE 2001, Philadelphia, USA, September 5 – 8, 2001p.144

2000

Migasena S, Suntharasamai P, Pitisuttithum P, Kitayaporn D, Wasi C, Huang W, Vanichseni S, Koompong C, Kaewkungwal J, Raktham S, ppolito T, Hanson C, Gregory T, Heyward WL, Berman P, Francis D. AIDSVAXÒ (MN) in Bangkok injecting drug user: A report on safety and immunogenicity including mocrophage tropic virus neutralizing. AIDS Res Hum Retroviruses 2000; 16:655-63.

Pitisuttithum P, and Thai AIDS Vaccine Evaluation Group. Phase II Trial of HIV-1 Subtype E and B gp120 Vaccines in Seronegative Thai Adults. (Abstract). XII International AIDS Conference Durban, South Africa, 9-14 July 2000

Pitisuttithum P, Bangkok Vaccine Evaluation Group. Social harm monitoring among injecting drug users (IDUs) in a phase III HIV vaccine trial in Bangkok, Thailand-preliminary results.(Abstract). XII International AIDS Conference Durban, South Africa, 9-14 July 2000 p.443

Pitisuttithum P, Phonrat B, Suntharasamai P, Raktham S, Srisuwanvilai L, Hiranrus K, Kitayaporn D., et al. Initial Report of a Phase I/II Safety and Immunogenicity Trial AIDSVSXTM B/E rgp120 HIV Vaccine – Bangkok, Thailand. (Abstract). XII International AIDS Conference Durban,South Africa, 9-14 July 2000

Pitisuttithum P, Phonrat B, Suntharasamai P, Raktham S, Srisuwanvilai L, Kitayaporn D, Kaewkangwal J, Migasean S, Hiranrus K, Berman P, Chernow M and Francis D. Phase I/II Safety and Immunogenicity Trial of Bivalent rgp120 HIV Vaccine (AIDSVAXTM B/E) in Bangkok, Thailand-Initial Report (Abstract). The Third Annual Conference on Vaccine Research, Washington DC. April 30-May 2, 2000 p.48

1999

Pitisuttithum P, Cohen MB, Phonrat B, Suthisarnsuntorn U, Bussaratid V, Phumratanaprapin W, Singhasivanon P, Looareesuwan S, Giannella RA, Schiff GM, Ivanoff B and Lang D. Validation of a human volunteer challenge model using frozen bacteria of the new epidemic serotype V.cholerae O139. Comparison of the inoculum dose response between North American and thai volunteers (Abstract). The 35th US-Japan Cholera and other Bacterial Enteric Infectious Baltimore, MD. December 3-5 1999; p.37

Pitisuttithum P, Phonrat B, Suntharasamai P, Migasena S, Bussaratid V, Francis DP, McNeil J, Brown A, Duliege AM. HIV-1 Vaccine trial at the Vaccine Trial Centre (VTC), Bangkok. (Abstract). The second annual conference on Vaccine research Bethesda, 28-30 March 1999

Pitisuttithum P, Phonrat B, Suntharasamai P, Raktham S, Srisuwanvilai L, Ktitayaporn D, Kaewkangwal J, Migasena S, Hiranrus K, Berman P and Francis D. A Phase I/II Trial to Evaluate the Safety and Immunogenicity of AIDSVAXTM B/E Vaccine Bangkok, Thailand-Priliminary Results. Kuala Lumpur, 23-27 October 1999

Pitisuttithum P, Tongcharoen P, Khamboonruang C, Nitayaphan S, Chiu J, Brown A. and McNeil J. HIV Subtype E gp 120 Vaccine Trial (Phase II) in Seronegative Thai Adults. Kuala Lumpur, 23-27 October 1999

1998

Francis D, Gregory T, McElrath J, Belshe R, Gorse G, Migasena S, Kitayaporn D, Pitisuttithum P, et al Advancing AIDSVAXTM to Phase III Safety, Immunogenicity and Plans for Phase III . AIDS Res Human Retroviruses 1998; 14 : S 325-31

Migasina S, Simasathien S, Samakoses R, Pitisuttithum P, Heath J, Bellini W and Bennett J. Adverse impact of infections on antibody responses to measles vaccination Vaccine.1998;16(6):647-52

Pitisuttithum P, Kambooruang C, Suntharasamai P, et al. Clinical response to HIV Thai E /MF59 vaccine administer of alone or combined with SF2 gp120 antigen in healthy volunteers (Abstract) 12th World AIDS Conference Geneva. June 28-July 3, 1998 page 636

Tansuphasawadikul S, Poprawski DM, Pitisuttithum P and Phonrat B. Non adherence in tuberculosis treatment among HIV patients attending Bamrasnaradura Hospital Nonthaburi. J Med assoc thai 1998; 81:964-9

1997

Migasena S, Heppner DG, Kyle DE, Chongsuphajaisiddhi T, Gordon DM, Suntharasamai P, Permpanich B, Brockman A, Pitisuttithum P, et al. SPf66 malaria vaccine is safe and immunogenic in malaria native adults in Thailand. Acta Tropica 1997; 67:215-27

Migasena S, Simasathien S, Desakorn V, Phonrat B, Suntharasamai P Pitisuttithum P, Aree C, Naksrisook S, Supeeranun L, Samakoses R, Meurice F. Seroprevalence of varicella-zoster Virus Antibody in Thailand. Int J Infect Dis 1997; 2:26-30.

Looareesuwan S, Wilairatana P, Vanijianonta S, Pitisuttithum P, Ratanapong Y and Andrial M. Monotherapy with sodium artesunate for uncomplicated falciparum malaria in Thailand: a comparison of 5-and 7- day regimens Acta Trop 1997;30;67(3):197-205

Looareesuwan S, Wilairatana P, Viravan C, Vanijanonta S, Pitisuttithum P and Kyle DE. Open randomized trial of oral artemether alone and a sequential combination with mefloquine for acute uncomplicated falciparum malaria. Am J Trop Med Hyg 1997; 56(6):613-7

Pitisuttithum P, Migasena S, Laothai A, Suntharasamai P, et al. Risk behaviour and comprehension among intravenous drug users volunteered for HIV vaccine trial. J Med Assoc Thai 1997; 80(1):47-50

Pitisuttithum P, Migasena S, Suntharasamai P and Raktham S. Experience to date with vaccine trial in recovering intravenous drug users: Lesson for the future. (Abstract). 4th International Congress on AIDS in Asia and the Pacific October 25-29,1997 p.360

Simasathien S, Migasena S, Bellini W, Samakoses R, Pitisuttithum P, Bupodom W, Heath J, Anderson L and Bennett J. Measles vaccination of Thai infants by intranasal and subcutaneous routes: possible interference from respiratory infections. Vaccine 1997; 15(3): 329-34

Suntharasamai P, Migasena S, Pitisuttithum P., et al. Recruiting recovering intravenous drug users for a HIV protective vaccine trial (Abstract). 4th international Congress on AIDS in Asia and the Pacific October 25-29, 1997 p.377

1996

Looareesuwan S, Viravan C, Vanijanonta S, Wilairatana P, Pitisuttithum P and Andrial M. Comparative Clinical Trial of Artesunate followed by Mefloquine in the treatment of acute uncomplicated falciparum malaria: two-and three day regimens. Ann J Trop Med Hyg 1996; 54(2):210-3

Looareesuwan S, Wilairatana P, Vanijanonta S, Pitisuttithum P and Viravan C. Treatment of acute,uncomplicated falciparum malaria with oral dihydroartemisinin. Ann Trop Med Parasit 1996; 90(1):21-8

Migasena S, Pitisuttithum P, Phonrat B. Combined Immunization of infants with oral and inactivated poliovirus vaccines:results of a randomized trial in the Gambia, Oman and Thailand. Bulletin of World Health Organization. 1996;74(3):253-68.

Migasena S, Sutharasamai P, Pitisuttithum P, Kitayaporn D, Wasi C,Vanichseni S, Koompong C, Kaewkungwal J, Raktham S, Ippolito T, Gregory T, Heyward WL and Francis DP. A phase I/II Trial of MN RGP 120 HIV-1 vaccine among injecting drug users Bangkok, Thailand Safety and Immunogenicity. (Abstract) XI Internation Conference on AIDS, Vancouver, July 7-12,1996p.41

Pittisuttithum P, Migasena S, Suntharasamai P, Sutthan R, Perathamanond P, Wasi C,Schikan U, Peeters P and Tobia A. Hypericin: Safety and Antiretroviral activity in Thai HIV positive volunteers (Abstract). XI Interantion Conference on AIDS, Vancouver, July 7-12,1996 p.285

1995

Migasena S, Simasathien S, Samakoses R, Pitisuttithum P, Sangaroon P, Steenis GV, Beuvery C, Bugg H, Bishop R, Davidson B and Vesikari T. Simultaneous administration of oral rhesus-human reassortant tetravalent (RRV-TV) rotavirus vaccine and oral poliovirus vaccine (OPV) in Thai infants. Vaccine 1995; 13(2):168

Pitisuttithum P, Phiboonnakit D, Chindanond D, Punpoonwong B, Leelasuphasri S and Vanijanond S. Intestinal Microsporidiosis: First reported case in Thailand. Southeast Asian J Trop Med Pub Hlth 1995; 26(2):378-80

Pitisuttithum P, Supanaranond W and Chindanond D. A randomized comparative study of albendazole and thiabendazole in chronic strongyloidasis. Southeast Asian J Trop Med Pub Health 1995; 26(4):735-8

Punpoowong B, Pitisuttithum P, Chindanon D, Phiboonnakit, D and Leelasuphasri S. Microsporidium: Modified technique for ligh microscopic diagnosis. J Med Assoc Thai 1995; 78(5):252-4

1994

Simasathien S, Migasena S, Samakoses R, Pitisuttithum P, Sangaroon P, Aree C, Bishop R, Bugg H, Davidson B and Vesikari T. Vaccination of Thai infants with rhesus-human reassortant tetravalent (PRV-TV) rotavirus vaccine Pediatr. Infect Dis J 1994;13(7):590

Simasathien S, Migasena S, Beuvery C, Steenis G, Samakoses R, Pitisuttithum P and Vesikari T. Comparison of enhanced potency inactiated poliovirus vaccine (eIPV) versus standard oral poliovirus vaccine (OPV) in Thai infants. Scan J Infect Dis1994; 26:731-8

1993

Pitisuttithum P, Migasena S, Prayurahong B, Supanaranond W, Suntharasamai P, Supeeranan L, Chantra A and Naksrisook S. Pasteur oral cholera vaccine studies of reactogenicity, clinical acceptability and immunogenicity in human volunteers. Southeast Asian J Trop Med Pub Hlth 1993; 24(1):126

1992

Su-arehawaratana P, Singharaj P, Taylor D N, Hoge C, Trofa A, Kuvanont K, Migasena S, Pitisuttithum P, Lim Y L, Losonsky G, Kaper JB, Wesserman SS, Cryz S, Echeverria P. and Levine MM. Safety and immunogenicity of different immunization regimens of CVD 103-HgR live oral cholera vaccine in soldiers and civilians in Thailand. J Infect Dis 1992;165(6):1042

Suntharasamai P, Migasena S, Vongsthongsri U, Supanaranond W, Pitisuttithum P, Supeeranan L, Chantra A and Naksrisook S. Clinical and bacteriological studies of El Tor cholera after ingestion of known inocula in Thai volunteers. Vaccine 1992; 10(8):502

1991

Migasena S, Pitisuttithum P and Desakorn V. Gnathostoma larva migrans among guests of a New Year party. Southeast Asian J Trop Med Public Health. 1991 Dec;22 suppl:225-7

1990

Migasena S, Pitisuttithum P, Prayurahong B, Supanaranond W, Desakorn V, Suntharasamai P, Vongthongsri U and Levine MM. Clinical acceptability immunogenicity colonizing potential and transmissibility of0 attenuated (A-B+) Vibrio cholerae classical Inaba live oral vaccine strain CVD 103-HgR in healthy young Thai adults. Infect Immun 1989; 57:3261

Pitisuttithum P, Migasena S, Juntra A, Supeeranun L and Naksrisuk S. Socioeconomic status and prevalence of interstial parasitic infection in Thai adults resideing in and around Bangkok metropolis. J Med Assoc Thai 1990; 73:522-3

Pitisuttithum P, Migasena S, Suntharasamai P, Supanaranond W, Desakorn V and Prayurahong B. Immune responses following killed whole vibrio-B subunit oral cholera vaccine in human volunteers. Southeast Asian J Trop Med Pub Hlth 1990; 20:201-5

Pitisuttithum P, Prayurahong B, Migasena S and Sunthrasamai P. Relationship of vibiocidal antibodies to history of cholera vaccination in Thai adult volunteers. Southeast Asian J Trop Med Pub Hlth 1990; 21:219-24

Supanaranond W, Migasena S, Pitisuttithum P and Suntharasamai P. Health status of Thai volunteer in a cholera vaccine trial. J Med Assoc Thai 1990; 73(10): 548-51

1989

Migasena S, Desakorn V, Suntharasamai P, Pitisuttithum P, Prayurahong B, Supanaranond W and Black RE. Immunogenicity of two formulations of oral cholera vaccine comprised of killed whole vibrios and the B subunit of cholera toxin. Infect Immun 1989; 57(1): 117-20

Migasena S, Pitisuttithum P, Prayurahong B, Suntharasamai P, Supanaranond W, Desakorn V, Vongthongsri U, Tall B, Ketley J, Losonsky G, et al. Preliminary assessment of the safety and immunogenicity of live oral cholera vaccine strain CVD 103-HgR in healthy Thai adults. Infect Immun 1989; 57(11);3261-4

Migasena S, Pitisuttithum P, Supanaranond W, Desakorn V, Prayurahong B and untharasamai P. Reactogenicity and immunogenicity of oral cholera vaccine in Thai volunteers. Southeast Asian J Trop Med Pub Hlth 1989; 19:423-8

Migasena S, Pitisuttithum P, Suntharasamai P, Prayurahong B, Supanaranond W, Desakorn V and Black RE. Comparison of the reactivities and of immunogenicities of Procholeragenoid and the B-subunit of cholera toxin in Thai Volunteers. Infect Immun 1989; 57:1942-5

Migasena S, Supanaranond W, Pitisuttithum P, Suntharasamai P and Supeeranun L. Dose finding studies of Procholeragenoid in Thai volunteers. Southeast Asian J Trop Med Pub Hlth 1989; 20:27-30

Pitisuttithum P, Migasena S, Suntharasamai P, Supanaranond W, Desakorn V and Prayurahong B. Immune responses following killed whole vibrio-B subunit oral cholera vaccine in human volunteers. Southeast Asian J Trop Med Public Health 1989; 20(2):201-5

1988

Migasena S, Desakorn V, Suntharasamai P, Pitisuttithum P, Prayurahong B and Suntharasamai P. Reactogenicity and immunogenicity of oral cholera vaccine in Thai Volunteers. Southeast Asian J Trop Med Pub Hlth 1988; 19:423-8

Pitisuttithum P, Migagena S, Suntharasama P and Supanaranond W. Factors influenzing the intestinal intubation in Thai adult volunteers. J Med Assoc Thai 1988; 71:351-4

Last updated: October 10, 2023